




RealRate

PHARMACEUTICAL 2021

Zymeworks BC Inc
Rank 147 of 394



The relative strengths and weaknesses of Zymeworks BC Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zymeworks BC Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 64% points. The greatest weakness of Zymeworks BC Inc is the variable Research and Development, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 312%, being 55% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	455,076
Cost of Goods Sold	0
Intangible Assets	17,319
Liabilities, Current	85,666
Liabilities, Non-Current	8,669
Other Assets	53,796
Other Compr. Net Income	0
Other Expenses	429
Other Liabilities	34,119
Other Net Income	7,345
Other Revenues	38,951
Property and Equipment	12,185
Research and Development	168,534
Selling, General and Administrative Expense	57,885

Output Variable	Value in 1000 USD
Assets	538,376
Liabilities	128,454
Expenses	226,848
Revenues	38,951
Stockholders Equity	409,922
Net Income	-180,552
Comprehensive Net Income	-180,552
BaseVar	469,987
ECR before Limited Liability	214%
Economic Capital Ratio	312%